Tag: rating

The following decision was adopted at the Extraordinary General Meeting of Shareholders of LITGRID AB (company code 302564383, registered address at Karlo Gustavo Emilio Manerheimo st. 8, LT-05131, Vilnius) which was held on 19 June 2025:

Aliso Viejo, CA , June 18, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., developer of the Life Backup Plan digital health platform, proudly announces its advancement to the second round of Pepperdine University’s Most Fundable Companies® 2025 competition. The company earned a “B” rating, reflecting “Great Potential” among a competitive national pool of startups evaluated for scalability, business fundamentals, and investor appeal.

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.